- Home
- ATNM vs BEDU Comparison
ATNM vs BEDU Comparison
Compare ATNM & BEDU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNM
- BEDU
- Stock Information
- Founded
- ATNM 2000
- BEDU 1994
- Country
- ATNM United States
- BEDU United Kingdom
- Employees
- ATNM N/A
- BEDU N/A
- Industry
- ATNM Biotechnology: Pharmaceutical Preparations
- BEDU Other Consumer Services
- Sector
- ATNM Health Care
- BEDU Real Estate
- Exchange
- ATNM Nasdaq
- BEDU Nasdaq
- Market Cap
- ATNM 49.0M
- BEDU 54.0M
- IPO Year
- ATNM N/A
- BEDU 2017
- Fundamental
- Price
- ATNM $1.72
- BEDU $1.80
- Analyst Decision
- ATNM Strong Buy
- BEDU
- Analyst Count
- ATNM 2
- BEDU 0
- Target Price
- ATNM $4.50
- BEDU N/A
- AVG Volume (30 Days)
- ATNM 176.2K
- BEDU 1.2K
- Earning Date
- ATNM 08-08-2025
- BEDU 09-02-2025
- Dividend Yield
- ATNM N/A
- BEDU N/A
- EPS Growth
- ATNM N/A
- BEDU N/A
- EPS
- ATNM N/A
- BEDU N/A
- Revenue
- ATNM N/A
- BEDU $224,321,752.00
- Revenue This Year
- ATNM N/A
- BEDU N/A
- Revenue Next Year
- ATNM N/A
- BEDU N/A
- P/E Ratio
- ATNM N/A
- BEDU N/A
- Revenue Growth
- ATNM N/A
- BEDU N/A
- 52 Week Low
- ATNM $1.03
- BEDU $1.35
- 52 Week High
- ATNM $2.41
- BEDU $2.19
- Technical
- Relative Strength Index (RSI)
- ATNM 54.44
- BEDU 61.34
- Support Level
- ATNM $1.60
- BEDU $1.65
- Resistance Level
- ATNM $1.79
- BEDU $1.91
- Average True Range (ATR)
- ATNM 0.10
- BEDU 0.02
- MACD
- ATNM 0.01
- BEDU 0.01
- Stochastic Oscillator
- ATNM 76.25
- BEDU 50.00
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
About BEDU Bright Scholar Education Holdings Limited each representing four
Bright Scholar Education Holdings Ltd operates as an education service provider. It is engaged in the provision of education services, including complementary education services, operation services for domestic schools, and education programs and services including independent schools and colleges in United Kingdom (the UK) and the United States (the U.S.) Kingdom. It nearly eight overseas school located in the United Kingdom and the United States. It has three reportable segments, including Overseas Schools, Complementary Education Services, and K-12 Operation Services. Key revenue is generated from Overseas Schools. From a geographical perspective: Key revenue is generated from China following UK, U.S., Canada and Singapore.